Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin’s lymphoma

Targeted Oncology

Volumn 10, Issue 1, 2015, Pages 141-151

  Keating, Gillian M ^a  

^a SPRINGER   (New Zealand)

Author keywords

CAL 101; Chronic lymphocytic leukaemia; GS 1101; Idelalisib; Non Hodgkin s lymphoma; Zydelig

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; GS 563117; IDELALISIB; MIDAZOLAM; OFATUMUMAB; PLACEBO; RIFAMPICIN; RITUXIMAB; UNCLASSIFIED DRUG; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER SURVIVAL; CELLULITIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEMATOLOGIC DISEASE; HUMAN; INFUSION RELATED REACTION; LOSS OF APPETITE; NAUSEA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; RASH; VOMITING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; PURINES; QUINAZOLINONES;

EID: 84925507179     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-015-0359-8     Document Type: Article

References (42)

1. National Comprehensive Cancer Network (2014) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): non-Hodgkin’s lymphoma (version 5.2014). https://www.nccn.org. Accessed 17 Dec 2014
2. Herman SEM, Johnson AJ (2012) Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res 18(15):4013–8
3. Pauls SD, Lafarge ST, Landego I et al (2012) The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol 3:224
4. Chang JE, Kahl BS (2014) PI3-kinase inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep 9(1):33–43
5. Gilead Sciences Inc. (2014) Zydelig® (idelalisib) tablets, for oral use: US prescribing information. http://www.zydelig.com. Accessed 17 Dec 2014
6. European Medicines Agency (2014) Zydelig (idelalisib) film-coated tablets: EU summary of product characteristics. http://www.ema.europa.eu/. Accessed 17 Dec 2014
7. Lannutti BJ, Meadows SA, Herman SE et al (2011) CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117(2):591–4
8. Hoellenriegel J, Meadows SA, Sivina M et al (2011) The phosphoinositide 3ʹ-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603–12
9. Ikeda H, Hideshima T, Fulciniti M et al (2010) PI3K/p110δ is a novel therapeutic target in multiple myeloma. Blood 116(9):1460–8
10. Davids MS, Deng J, Wiestner A et al (2012) Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 120(17):3501–9
11. Fiorcari S, Brown WS, McIntyre BW et al (2013) The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS ONE 8(12):e83830
12. Herman SEM, Gordon AL, Wagner AJ et al (2010) Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116(12):2078–88
13. Meadows SA, Vega F, Kashishian A et al (2012) PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119(8):1897–900
14. Herter S, Palazzo A, Bacac M, et al. (2014) The PI3K delta selective inhibitor idelalisib does not interfere with immune effector function and B cell depletion mediated by obinutuzumab (GA101) and rituximab [abstract no. 3342]. In: 56th American Society of Hematology Annual Meeting and Exposition
15. Jin F, Robeson M, Zhou H, et al. (2013) Evaluation of the effect of idelalisib on the QT/QTC interval in healthy subjects [abstract no. 5573]. Blood 122(21)
16. Webb HK, Chen H, Yu AS, et al. (2010) Clinical pharmacokinetics of CAL-101, a p110 isoform-selective P13Kδ inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies [abstract no. 1774 plus poster]. Blood 116(21)
17. Jin F, Robeson M, Zhou H, et al. (2013) Evaluation of drug interaction profile of idelalisib and its major circulating metabolite, GS-563117, in healthy subjects [abstract no. 5574]. Blood 122(21)
18. Jin F, Robeson M, Zhou H, et al. (2013) Pharmacokinetics, metabolism and excretion of idelalisib [abstract no. 5570]. Blood 122(21)
19. Jin F, Robeson M, Zhou H, et al. (2013) The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment [abstract no. 5571]. Blood 122(21)
20. Jin F, Robeson M, Zhou H, et al. (2013) The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment [abstract no. 5572]. Blood 122(21)
21. Jin F, Robeson M, Zhou H, et al. (2013) Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects [abstract no. 5575]. Blood 122(21)
22. Brown JR, Byrd JC, Coutre SE et al (2014) Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 123(22):3390–7
23. Barrientos JC, Furman RR, Leonard J, et al. (2013) Update on a phase I study of the selective PPI3Kδ inhibitor idelalisib (GS-101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL [abstract no. 7017 plus slide presentation]. J Clin Oncol 31(15 Suppl 1)
24. Furman RR, De Vos S, Leonard JP, et al. (2013) A phase 1 study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia [abstract no. 4180]. Blood 122(21)
25. Coutre S, Leonard J, Furman R, et al. (2013) Update on a phase I study of the selective PI3K-delta inhibitor, idelalisib (GS-1101) in combination with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukaemia [abstract no. S1150]. In: 18th Congress of the European Hematology Association
26. Barrientos JC, Coutre SE, De Vos S, et al. (2014) Long-term follow-up of a phase I study evaluating the selective PI3Kδ inhibitor idelalisib in combination with bendamustine (B), bendamustine/rituximab (BR), fludarabine (F), chlorambucil (Chl), or chlorambucil/rituximab (ChlR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) [abstract no. 3343]. In: 56th American Society of Hematology Annual Meeting and Exposition
27. Furman RR, Sharman JP, Coutre SE et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997–1007
28. Gopal AK, Kahl BS, de Vos S et al (2014) PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008–18
29. Pagel JM, Coutre SE, Furman RR, et al. (2014) Second interim analysis of a phase 3 study evaluating idelalisib plus rituximab for relapsed chronic lymphocytic leukemia (CLL) [poster]. In: Second Annual Meeting of the Society of Hematologic Oncology
30. Coutre SE, Furman RR, Sharman JP, et al. (2014) Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL [abstract no. 7012 plus poster]. J Clin Oncol 32(5 Suppl).
31. Sharman JP, Coutre SE, Furman RR, et al. (2014) 2nd interim analysis of a phase 3 study of idelalisib (Zydelig®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract no. 330]. In: 56th American Society of Hematology Annual Meeting and Exposition
32. Sharman JP, Coutre SE, Furman RR, et al. (2014) Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: results from a phase 3, randomized, double-blind, placebo-controlled trial [abstract no. 7011 plus poster]. J Clin Oncol 32(15 Suppl 1)
33. Ghia P, O’Brien SM, Hillmen P, et al. (2014) Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): phase 3 results [abstract no. 7099 plus poster]. J Clin Oncol 32(5 Suppl)
34. Xenakis A, Smith N, Beckerman R, et al. (2014) A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia [abstract no. 7101]. J Clin Oncol 32(15 Suppl 1)
35. Gopal AK, Kahl BS, de Vos S, et al. (2014) Mature follow up from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL) [abstract no. 1708]. In: 56th American Society of Hematology Annual Meeting and Exposition
36. Flinn IW, Kahl BS, Leonard JP et al (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123(22):3406–13
37. Wagner-Johnston ND, Gopal AK, Kahl BS, et al. (2014) Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL) [abstract no. e19554]. J Clin Oncol 32(15 Suppl 1)
38. Smith N, Xenakis A, Beckerman R, et al. (2014) A decision-analytic model of idelalisib in relapsed or refractory patients with indolent non-Hodgkin lymphoma [abstract no. e17655]. J Clin Oncol 32(15 Suppl 1)
39. O’Brien S, Lamanna N, Kipps TJ, et al. (2014) Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naive patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) [abstract no. 1994]. In: 56th American Society of Hematology Annual Meeting and Exposition
40. Zelenetz A, Lamanna N, Kipps T, et al. (2014) A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract no. 1986 plus poster]. In: 56th American Society of Hematology Annual Meeting and Exposition
41. de Vos S, Wagner-Johnston ND, Coutre SE, et al. (2014) Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: phase I/II results [abstract no. 3063]. In: 56th American Society of Hematology Annual Meeting and Exposition
42. Cheson BD, Byrd JC, Rai KR et al (2012) Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 30(23):2820–2